Publications

Multikinase or tyrosine kinase inhibitors (TKI) are currently approved for radioiodine-refractory metastatic differentiated thyroid carcinoma patients. There are some anecdotal reports of the use of TKI inhibitors in the neoadjuvant setting in DTC (differentiated thyroid carcinoma) patients. But there is not much experience regarding the use of these agents in this setting. In this report, we describe the case of a 45-year-old man with unresectable locally infiltrative follicular thyroid carcinoma who underwent successful R0 resection following neoadjuvant therapy with Sorafenib. Sorafenib could be effective as neoadjuvant therapy in selected cases of locally advanced DTC.